Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the re-investment of dividends paid on July 9, 2009.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Ordinary Share Purchase Price: £11.23 per share (purchased July 15, 2009).
- ADR Purchase Price: $35.12 per ADR (purchased July 9, 2009).
Material Changes
The filing details an increase in share interests for various executives following the dividend re-investment plan. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of specific share purchases.
Important Facts for Investors to Verify
- Verify the total number of shares and ADRs purchased by each listed executive to assess insider confidence levels.
- Confirm the dividend amount per share implied by the re-investment transaction prices (£11.23 and $35.12).
- Check subsequent filings for any changes in executive holdings beyond this specific dividend re-investment event.